Yervoy (ipilimumab) is a medication used to treat certain types of cancer. According to the drug patent watch website [1], the patent for Yervoy expired in 2022, which means that generic versions of the medication may become available. However, as of now, there is no generic version of Yervoy available in the market.

The package insert for Yervoy [2] states that the recommended dose of Yervoy is 3 mg/kg administered intravenously over 90 minutes every 3 weeks for a total of 4 doses. The discount program for Yervoy is offered by Bristol-Myers Squibb, the manufacturer of the drug, and is available for eligible patients who have commercial insurance. According to the Aetna website [3], the discount program for Yervoy provides eligible patients with a savings card that can be used to reduce the out-of-pocket costs for the medication.

However, it is not clear from the sources provided whether the discount program for Yervoy is applicable for all doses. It is recommended that patients who are interested in the discount program for Yervoy contact Bristol-Myers Squibb or their healthcare provider for more information about the program and its eligibility requirements.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY
[2] https://packageinserts.bms.com/pi/pi_yervoy.pdf
[3] https://www.aetna.com/cpb/medical/data/800_899/0815.html